

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6 K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

EDAP TMS S.A. Files

EDAP TMS S.A. Announces \$7.5 Million Placement

July 27, 2006

EDAP TMS S.A.
Parc Activite La Poudrette Lamartine
4/6 Rue du Dauphine
69120 Vaulx-en-Velin - France

Indicate by check mark whether the registrant files or will file
annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

EDAP TMS S.A. ANNOUNCES \$7.5 MILLION PLACEMENT

LYON, France, July 27 /PRNewswire-FirstCall/ -- EDAP TMS S.A.
(Nasdaq: EDAP) announced that it has entered into a securities purchase
agreement with selected accredited investors pursuant to which an aggregate of
961,676 of the company's ordinary shares in the form of American Depositary
Shares are expected to be issued at a per ADS price of \$7.75. The closing of the
financing is expected to occur on or about August 3, 2006, subject to certain
customary closing conditions contained in the definitive transaction agreements.
Net proceeds from the financing will total approximately \$6.5 million after
offering expenses. Proceeds are expected to be used primarily to fund marketing
efforts to promote the use of EDAP's High Intensity Focused Ultrasound treatment
for prostate cancer, Ablatherm, among physicians and patients located in key
countries in Europe.

The securities offered herein have not been registered under the Securities
Act of 1933, as amended, and may not be offered or sold in the United States
absent registration or an applicable exemption from registration requirements.
As part of the transaction, the company has agreed to file a resale registration
statement on Form F-3 with the Securities and Exchange Commission within 30 days
following the closing for the purpose of registering for resale the American
Depositary Shares evidencing the ordinary shares sold in the offering.

This press release shall not constitute an offer to sell or a solicitation
of an offer to buy, nor shall there be, absent any exemption therefrom, any sale
of these securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction.

This press release contains, in addition to historical information,
forward-looking statements that involve risks and uncertainties. These include
statements regarding the Company's growth and expansion plans. Such statements
are based on management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ materially
from those described in the forward-looking statements. Factors that may cause
such a difference include, but are not limited to, those described in the
Company's filings with the Securities and Exchange Commission. Ablatherm-HIFU
treatment is in clinical trials but not yet FDA approved or marketed in the
United States.

CONTACT: EDAP TMS S.A.
Hugues de Bantel - Philippe Chauveau
Blandine Confort

+33 4 78 26 40 46

Halliburton Investor Relations
Matt Kreps - Geralyn DeBusk
972 458 8000

SOURCE EDAP TMS SA

-0-

07/27/2006

/CONTACT: Hugues de Bantel, Blandine Confort, or Philippe Chauveau all of
EDAP TMS S.A., +33-4-78-26-40-46; or Matt Kreps, or Geralyn DeBusk, both of
Halliburton Investor Relations, +1-972-458-8000, for EDAP TMS SA/

/Web site: <http://www.edap-tms.com/>

(EDAP)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date : July 27, 2006
EDAP TMS S.A.

/S/ HUGUES DE BANTEL

HUGUES DE BANTEL
CHIEF EXECUTIVE OFFICER